Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting

Rhea-AI Summary

Hemogenyx Pharmaceuticals announced the successful passing of all resolutions at its Annual General Meeting held on June 27, 2024. Key resolutions included the adoption of the company's annual accounts, approval of the Directors' Remuneration Report, re-appointment of Sir Marc Feldmann as Director, and re-appointment of PKF Littlejohn LLP as auditors. The voting results showed strong approval from shareholders, with most resolutions receiving over 90% votes in favor. Highlights include a 99.89% approval for the annual accounts and a 99.10% approval for the re-appointment of auditors. The resolutions enable the company to continue its strategic objectives and operational plans effectively.

Positive

• All resolutions passed at the AGM, signaling strong shareholder support.
• 99.89% approval for the company's annual accounts for the year ended 31 December 2023.
• Directors' Remuneration Report approved with 90.14% votes in favor.
• Re-appointment of Sir Marc Feldmann as a Director approved by 97.51% of votes.
• Re-appointment of PKF Littlejohn LLP as auditors received 99.10% approval.

Negative

• None.

LONDON, UNITED KINGDOM / ACCESSWIRE / June 27, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.

Proxy Voting Results

Ordinary Resolutions	Votes for	% of votes cast for	Votes Against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes with-held (2)
1. To receive and adopt the Company's annual accounts for the year ended 31 December 2023.	172,981,350	99.89	189,346	0.11	173,170,696	12.91	804,255
2. To approve the Directors' Remuneration Report which is set out in the 2023 Annual Report and Accounts.	155,914,909	90.14	17,056,623	9.86	172,971,532	12.89	1,003,419
3. To re-appoint Sir Marc Feldmann as a Director of the Company.	168,819,296	97.51	4,316,573	2.49	173,135,869	12.90	839,082
4. To re-appoint PKF Littlejohn LLP as auditor of the Company to hold office until the conclusion of the next Annual General Meeting of the Company.	156,805,252	99.10	1,429,684	0.90	158,234,936	11.79	15,740,015
5.​ To authorise the Audit Committee to agree the auditor's remuneration​.	157,329,629	90.99	15,576,903	9.01	172,906,532	12.89	1,068,419
6. To authorise the Directors to allot shares pursuant to section 551 of the Companies Act 2006.​	153,328,931	88.71	19,513,766	11.29	172,842,697	12.88	1,132,254
Special Resolutions	Votes for	% of votes cast for	Votes against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes with-held (2)
7. To disapply pre-emption rights under section 570 of the Companies Act 2006.	152,661,902	88.30	20,235,808	11.70	172,897,710	12.89	1,077,241
8. To approve for calling of general meetings (other than AGMs) on 14 days' notice.	172,081,747	99.38	1,080,015	0.62	173,161,762	12.91	813,189

(1) The Company's issued share capital ("ISC") on 25 June 2024, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 1,341,815,988 ordinary shares.

(2) A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View the original press release on accesswire.com

FAQ

What were the results of Hemogenyx Pharmaceuticals' AGM votes on June 27, 2024?

All resolutions were passed at the AGM, with significant shareholder support, including 99.89% approval for the annual accounts.

What percentage of votes approved Hemogenyx Pharmaceuticals' annual accounts for 2023?

The annual accounts for the year ended 31 December 2023 were approved with 99.89% of the votes.

Did Hemogenyx Pharmaceuticals' shareholders approve the Directors' Remuneration Report in the 2024 AGM?

Yes, the Directors' Remuneration Report was approved with 90.14% of the votes.

Was Sir Marc Feldmann re-appointed as a Director at Hemogenyx Pharmaceuticals' 2024 AGM?

Yes, Sir Marc Feldmann was re-appointed as a Director with 97.51% of shareholder votes in favor.

Who was re-appointed as the auditor for Hemogenyx Pharmaceuticals at the 2024 AGM?

PKF Littlejohn LLP was re-appointed as the auditor with 99.10% of the votes.